The epidemiology of age-related macular degeneration

International Ophthalmology Clinics

Volumn 44, Issue 4, 2004, Pages 17-39

  Seddon, Johanna M ^a   Chen, Clara A ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA CAROTENE; COPPER; CUPRIC OXIDE; ESTROGEN; HYPOCHOLESTEROLEMIC AGENT; STATINE DERIVATIVE; UNCLASSIFIED DRUG; ZINC; ZINC OXIDE;

ALCOHOL CONSUMPTION; BLINDNESS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CATARACT; CATARACT EXTRACTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DIABETES MELLITUS; DIET; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ENVIRONMENTAL FACTOR; ESTROGEN THERAPY; ETHNIC DIFFERENCE; FAT INTAKE; GENETIC LINKAGE; HEREDITY; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INCIDENCE; INFLAMMATION; IRIS; NUTRITIONAL STATUS; OBESITY; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RACE DIFFERENCE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SMOKING; SOCIOECONOMICS; SUBRETINAL NEOVASCULARIZATION; SUN EXPOSURE; VISION;

AGE DISTRIBUTION; AGED; FEMALE; HUMANS; INCIDENCE; MACULAR DEGENERATION; MALE; PREVALENCE; RISK FACTORS; SEX DISTRIBUTION;

EID: 6344241300     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-200404440-00004     Document Type: Review

References (170)

1. National Advisory Eye Council (US). Vision Research: A National Plan 1994-1998. Bethesda, MD: U.S. Department of Health and Human Services; 1993:NIH pub no 93-3186.
2. National Institute for Neurological Diseases and Blindness. Section on Blindness Statistics. Statistics on Blindness in the Model Reporting Area, 1969-1970, U.S. Department of Health Education, and Welfare. Washington, D.C.: U.S. Government Printing Office; 1973:DHEW pub no (NIH) 73-427.
3. Age-Related Eye Disease Study Research Group. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol. 2003;121:1621-1624.
4. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-572.
5. Thylefors B. A global initiative for the elimination of avoidable blindness. Am J Ophthalmol. 1998;125:90-93.
6. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417-1436.
7. Seddon JM, Hankinson S, Speizer F, et al. A prospective study of smoking and age-related macular degeneration. Am J Epidemiol 1995;241:136.
8. Seddon JM, Willett WC, Speizer FE, et al. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA. 1996;276:1141-1146.
9. Cho E, Hung S, Willett WC, et al. Prospective study of dietary fat and the risk of age-related macular degeneration. Am J Clin Nutr. 2001;73:209-218.
10. Cho E, Seddon JM, Rosner B, et al. Prospective study of intake of fruits, vegetables, vitamins, and carotenoids and risk of age-related maculopathy. 2004;122:883-896.
11. Eye Disorders Case-Control Study Group. Antioxidant status and neovascular age-related macular degeneration. Arch Ophthalmol. 1993;111:104-109.
12. Mares-Perlman JA, Brady WE, Klein R. Dietary fat and age-related maculopathy. Arch Ophthalmol. 1995;113:743-748.
13. Mares-Perlman JA, Brady WE, Klein R, et al. Serum antioxidants and age-related macular degeneration in a population-based case-control study. Arch Ophthalmol. 1995;113:1518-1523.
14. Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. JAMA. 1994;272:1413-1420.
15. Seddon JM, Ajani U, Sperduto R, et al. Dietary fat intake and age-related macular degeneration. Invest Ophthalmol Vis Sci. 1994;25:2003.
16. Seddon JM, Hennekens CH. Vitamins, minerals, and macular degeneration. Arch Ophthalmol. 1994;112:176-179.
17. Seddon JM, Rosner B, Sperduto RD, et al. Dietary fat and risk for advanced age-related macular degeneration. Arch Ophthalmol. 2001;119:1191-1199.
18. Seddon JM, Cote J, Davis N, et al. Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol. 2003;121:785-792.
19. Bressler NM, Bressler SB, West SK, et al. The grading and prevalence of macular degeneration in Chesapeake Bay watermen. Arch Ophthalmol. 1989;107:847-852.
20. Seddon JM, Gragoudas E, Egan K. Standardized data collection and coding in eye disease epidemiology: the uveal melanoma data system. Ophthalmic Surg. 1991;22:127-136.
21. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv Ophthalmol. 1995;39:367-374.
22. Afshari MA, Sharma S, Seddon JM. Evaluation of the Clinical Age-related Maculopathy Staging System (CARMS). Presented at: American Academy of Ophthalmology annual meeting; 2000.
23. Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study (AREDS): design implications AREDS report no. 1. Control Clin Trials. 1999;20:573-600.
24. Seddon JM, Samelson U, Page WF, et al. Twin study of macular degeneration: methodology and application to genetic epidemiologic studies. Invest Ophthalmol Vis Sci. 1996;38:676.
25. Seddon JM, Santangelo SL, Book K, et al. A genomewide scan for age-related macular degeneration provides evidence for linkage to several chromosomal regions. Am J Hum Genet. 2003;73:780-790.
26. Seddon JM, Cote J, Rosner B. Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake. Arch Ophthalmol. 2003;121:1728-1737.
27. Klein R, Davis MD, Magli YL, et al. The Wisconsin age-related maculopathy grading system. Ophthalmology. 1991;98:1128-1134.
28. Ganley J, Roberts J. Eye Conditions and Related Need for Medical Care Among Persons 1-74 Years of Age, United States, 1971-1972. Vital and Health Statistics, series 11, no 228. Washington, D.C.: DHHS; 1983.
29. Klein R, Rowland ML, Harris MI. Racial/ethnic differences in age-related maculopathy: Third National Health and Nutrition Examination Survey. Ophthalmology. 1995;102:371-381.
30. Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study Monograph. Surv Ophthalmol. 1980;24(suppl):335-610.
31. Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy. Ophthalmology. 1992;99:933.
32. Friedman DS, Katz J, Bressler NM, et al. Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. Ophthalmology. 1999;106:1049-1055.
33. West SK, Muñoz B, Rubin GS, et al. Function and visual impairment in a population-based study of older adults. The SEE project. Salisbury Eye Evaluation. Invest Ophthalmol Vis Sci. 1997;38:72-82.
34. Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995;102:205-210.
35. Mitchell P, Smith W, Attebo K, et al. Prevalence of age-related maculopathy in Australia: The Blue Mountains Eye Study. Ophthalmology. 1995;102:1450-1460.
36. Schachat AP, Hyman L, Leske C, et al. Features of age-related macular degeneration in a black population. Arch Ophthalmol. 1995;113:728-735.
37. Pagliarim S, Moramarco A, Wormald RPL, et al. Age-related macular disease in rural southern Italy. Arch Ophthalmol. 1997;115:616-622.
38. National Center for Health Statistics. Plan and operation of the NHANES III: United States 1988-1994. Vital Health Statistics. Vol 1. Washington, D.C.: National Center for Health Statistics; 1994.
39. Podgor MJ, Leske MC, Ederer F. Incidence estimates for lens changes, macular changes, open-angle glaucoma and diabetic retinopathy. Am J Epidemiol. 1983;118:208-212.
40. Klein R, Klein BEK, Jensen SC, et al. The five-year incidence and progression of age-related maculopathy. Ophthalmology. 1997;104:7-21.
41. Mukesh BN, Dimitrov PN, Leikin S, et al. Five-Year Incidence of Age-Related Maculopathy: The Visual Impairment Project. Ophthalmology. 2004;111:1176-1182.
42. Leske MC, Wu SY, Hyman L, et al. Barbados Eye Studies Group. Four-year incidence of macular changes in the Barbados Eye Studies. Ophthalmology. 2004;111:706-711.
43. Alexander MF, Maguire MG, Lietman TM, et al. Assessment of visual function in patients with age-related macular degeneration and low visual acuity. Arch Ophthalmol. 1988;105:1543-1547.
44. Davis C, Lovie-Kitchin J, Thompson B. Psychosocial adjustment to age-related macular degeneration. J Vision Impair Blind. 1995;1:16-27.
45. Mangione CM, Gutierrez P, Lowe G, et al. Influence of age-related maculopathy on visual functioning and health-related quality of life. Am J Ophthalmol. 1999;128:45-53.
46. Age-Related Eye Disease Study Research Group. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10. Arch Ophthalmol. 2003;121:211-217.
47. Brody BL, Gamst AC, Williams RA, et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology. 2001;108:1893-1900; discussion 1900-1901.
48. Casten RJ, Rovner BW, Tasman W. Age-related macular degeneration and depression: a review of recent research. Curr Opin Ophthalmol. 2004;15:181-183.
49. Rovner BW, Casten RJ, Tasman WS. Effect of depression on vision function in age-related macular degeneration. Arch Ophthalmol. 2002;120:1041-1044.
50. Javitt JC, Zhou Z, Maguire MG, et al. Incidence of exudative age-related macular degeneration among elderly Americans. Ophthalmology. 2003;110:1534-1539.
51. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in East Baltimore. N Engl J Med. 1991;325:1412-1417.
52. Cruickshanks KJ, Hamman RF, Klein R, et al. The prevalence of age-related maculopathy by geographic region and ethnicity. Arch Ophthalmol. 1997;115:242-250.
53. Varma R, Paz SH, Azen SP, et al. Los Angeles Latino Eye Study Group. The Los Angeles Latino Eye Study: design, methods, and baseline data. Ophthalmology. 2004;111:1121-1131.
54. Oshima Y, Ishibashi T, Murata T, et al. Prevalence of age related maculopathy in a representative Japanese population: the Hisayama study. Br J Ophthalmol. 2001;85:1153-1157.
55. Miyazaki M, Nakamura H, Kubo M, et al. Risk factors for age related maculopathy in a Japanese population: the Hisayama study. Br J Ophthalmol. 2003;87:469-472.
56. Das BN, Thompson JR, Patel R, et al. The prevalence of eye disease in Leicester: a comparison of adults of Asian and European descent. J R Soc Med. 1994;87:219-222.
57. Adler NE, Boyce WT, Chesney MA, et al. Socioeconomic inequalities in health: no easy solution. JAMA. 1993;269:3140-3145.
58. Eye Disease Case-Control Study Group. Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol. 1992;110:1701-1708.
59. Klein R, Klein BEK, Jensen SC, et al. The relation of socioeconomic factors to age-related cataract, maculopathy and impaired vision. Ophthalmology. 1994;101:1969-1979.
60. Hyman LG, Lilienfeld AM, Ferris FL, et al. Senile macular degeneration: a case-control study. Am J Epidemiol. 1983;118:213-227.
61. Chaine G, Hullo A, Sahel J, et al. Case-control study of the risk factors for age related macular degeneration. France-DMLA Study Group. Br J Ophthalmol. 1998;82:996-1002.
62. Maltzman BA, Mulvihill MN, Greenbaum A. Senile macular degeneration and risk factors: a case-control study. Ann Ophthalmol. 1979;11:1197-1201.
63. Wang JJ, Mitchell P, Smith W. Refractive error and age-related maculopathy: The Blue Mountains Eye Study. Invest Ophthalmol Vis Sci. 1998;39:2167-2171.
64. Ikram MK, van Leeuwen R, Vingerling JR, et al. Relationship between refraction and prevalent as well as incident age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci. 2003;44:3778-3782.
65. Frank RN, Puklin JE, Stock C, et al. Race, iris color, and age-related macular degeneration. Trans Am Ophthalmol Soc. 2000;98:109-115.
66. Holz FG, Piguet B, Minassian DC, et al. Decreasing stromal iris pigmentation as a risk factor for age-related macular degeneration. Am J Ophthalmol. 1994;117:19-23.
67. Mitchell P, Smith W, Wang JJ. Iris color, skin sun sensitivity, and age-related maculopathy. The Blue Mountains Eye Study. Ophthalmology. 1998;105:1359-1363.
68. Sandberg MA, Gaudio AR, Miller S, et al. Iris pigmentation and extent of disease in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 1994;35:2734-2740.
69. Weiter JJ, Delori FC, Wing GL, et al. Relationship of senile macular degeneration to ocular pigmentation. Am J Ophthalmol. 1985;99:185-187.
70. Gibson JM, Shaw DE, Rosenthal AR. Senile cataract and senile macular degeneration: an investigation into possible risk factors. Trans Ophthalmol Soc U K. 1986;105:463-468.
71. Klein R, Klein BEK, Jensen SC, et al. The relationship between ocular factors to the incidence and progression of age-related maculopathy. Arch Ophthalmol. 1998;116:506-513.
72. Tomany SC, Klein R, Klein BE. Beaver Dam Eye Study. The relationship between iris color, hair color, and skin sun sensitivity and the 10-year incidence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 2003;110:1526-1533.
73. Wang JJ, Jakobsen K, Smith W, et al. Five-year incidence of age-related maculopathy in relation to iris, skin or hair colour, and skin sun sensitivity: the Blue Mountains Eye Study. Clin Experiment Ophthalmol. 2003;31:317-321.
74. West SK, Rosenthal FS, Bressler NM, et al. Exposure to sunlight and other risk factors for age-related macular degeneration. Arch Ophthalmol. 1989;107:875-879.
75. Sperduto R, Hiller R, Seigel D. Lens opacities and senile maculopathy. Arch Ophthalmol. 1981;99:1004-1008.
76. Liu IY, White L, LaCroix AZ. The association between age-related macular degeneration and lens opacities in the aged. Am J Public Health. 1989;79:765-769.
77. Klein R, Klein BE, Wang Q, et al. Is age-related maculopathy associated with cataracts? Arch Ophthalmol. 1994;112:191-196.
78. Lundstrom M, Brege KG, Floren I, et al. Cataract surgery and quality of life in patients with age related macular degeneration. Br J Ophthalmol. 2002;86:1330-1335.
79. Freeman EE, Munoz B, West SK, et al. Is there an association between cataract surgery and age-related macular degeneration? Data from three population-based studies. Am J Ophthalmol. 2003;135:849-856.
80. Pollack A, Marcovich A, Bukelman A, et al. Age-related macular degeneration after extracapsular cataract extraction with intraocular lens implantation. Ophthalmology. 1996;103:1546-1554.
81. Christen WG, Glyim RJ, Manson JE, et al. A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA. 1996;276:1147-1151.
82. Klein R, Klein BEK, Franke T. The relationship of cardiovascular disease and its risk factors to age-related maculopathy. Ophthalmology. 1993;100:406-414.
83. Klein R, Klein BE, Tomany SC, et al. Ten-year incidence of age-related maculopathy and smoking and drinking: the Beaver Dam Eye Study. Am J Epidemiol. 2002;156:589-598.
84. POLA Study Group. Smoking and age-related macular degeneration. The POLA Study. Pathologies Oculaires Liees a l'Age. Arch Ophthalmol. 1998;116:1031-1035.
85. Suner IJ, Espinosa-Heidmann DG, Marin-Castano ME, et al. Nicotine increases size and severity of experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2004;45:311-317.
86. Bone RA, Landrum JT, Guerra LH, et al. Lutein and zeaxanthin dietary supplements raise macular pigment density and serum concentrations of these carotenoids in humans. J Nutr. 2003;133:992-998.
87. Krinsky NI, Landrum JT, Bone RA. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. Annu Rev Nutr. 2003;23:171-201.
88. Hung S, Seddon JM. The relationship between nutritional factors and age-related macular degeneration. In: Bendich A, and Deckelbaum R, eds. Preventive Medicine: The Comprehensive Guide for Health Professionals. Totowa, NJ: Humana Press; 1997.
89. Evereklioglu C, Er H, Doganay S, et al. Nitric oxide and lipid peroxidation are increased and associated with decreased antioxidant enzyme activities in patients with age-related macular degeneration. Doc Ophthalmol. 2003;106:129-136.
90. Sperduto RD, Ferris FL, Kuriij N. Do we have a nutritional treatment for age-related cataract or macular degeneration? Arch Ophthalmol. 1990;108:1403-1405.
91. Anderson RE, Kretzer FL, Rapp LM. Free radicals and ocular disease. Adv Exp Med Biol. 1994;366:73-86.
92. Anderson RE, Rapp LM, Wiegand RD. Lipid peroxidation and retinal degeneration. Curr Eye Res. 1984;3:223-227.
93. Young RW. Pathophysiology of age-related macular degeneration. Surv Ophthalmol. 1987;31:291-306.
94. Hopley C, Salkeld G, Wang JJ, et al. Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants. Br J Ophthalmol. 2004;88:450-454.
95. Richer S, Stiles W, Statkute L, et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry. 2004;75:216-230.
96. Gale CR, Hall NF, Phillips DI, et al. Lutein and zeaxanthin status and risk of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2003;44:2461-2465.
97. Goldberg J, Flowerdew G, Smith E, et al. Factors associated with age-related macular degeneration: an analysis of data from the first National Health and Nutrition Examination Survey. Am J Epidemiol. 1988;128:700-710.
98. Ajani UA, Willett W, Miller D, et al. Alcohol consumption and neovascular age-related macular degeneration. Am J Epidemiol. 1993;138:646.
99. Vinding T, Appleyard M, Nyboe J, et al. Risk factor analysis for atrophic and exudative age-related macular degeneration: an epidemiologic study of 1000 aged individuals. Acta Ophthalmology. 1992;70:66-72.
100. Obisesan TO, Hirsch R, Kosoko O, et al. Moderate wine consumption is associated with decreased odds of developing age-related macular degeneration in NHANES-1. J Am Geriatr Soc. 1998;46:1-7.
101. Seddon JM, Cho E, Stampfer M, et al. Prospective study of alcohol consumption and the risk of age-related macular degeneration. Invest Ophthalmol Vis Sci. 1999;40:568.
102. Smith W, Mitchell P. Alcohol intake and age-related maculopathy. Am J Ophthalmol. 1996;122:743-745.
103. Klein BE, Klein R, Lee KE, et al. Measures of obesity and age-related eye diseases. Ophthalmic Epidemiol. 2001;8:251-262.
104. POLA Study Group. Associations of cardiovascular disease and its risk factors with age-related macular degeneration: the POLA study. Ophthalmic Epidemiol. 2001;8:237-249.
105. Schaumberg DA, Christen WG, Hankinson SE, et al. Body mass index and the incidence of visually significant age-related maculopathy in men. Arch Ophthalmol. 2001;119:1259-1265.
106. Smith W, Mitchell P, Leeder SR, et al. Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol. 1998;116:583-587.
107. Cruickshanks KJ, Klein R, Klein BEK. Sunlight and age-related macular degeneration: The Beaver Dam Eye Study. Arch Ophthalmol. 1993;111:514-518.
108. Cruickshanks KJ, Klein R, Klein BE, et al. Sunlight and the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol. 2001;119:246-250.
109. Tomany SC, Cruickshanks KJ, Klein R, et al. Sunlight and the 10-year incidence of age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol. 2004;122:750-757.
110. POLA Study Group. Light exposure and the risk of age-related macular degeneration: the Pathologies Oculaires Liees a l'Age (POLA) study. Arch Ophthalmol. 2001;119:1463-1468.
111. Darzins P, Mitchell P, Heller RF. Sun exposure and age-related macular degeneration: an Australian case-control study. Ophthalmology. 1997;104:770-776.
112. Age-Related Macular Degeneration Risk Factors Study Group. Hypertension, cardiovascular disease, and age-related macular degeneration. Arch Ophthalmol. 2000;118:351-358.
113. Wilson HL, Schwartz DM, Bhatt HR, et al. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol. 2004;137:615-624.
114. Hall NF, Gale CR, Syddall H, et al. Risk of macular degeneration in users of statins: cross sectional study. Br Med J. 2001;323:375-376.
115. van Leeuwen R, Vingerling R, Hofman A, et al. Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement. Br Med J. 2003;326:255-256.
116. Klein R, Klein BE, Jensen SC, et al. Medication use and the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol. 2001;119:1354-1359.
117. Klein R, Klein BE, Tomany SC, et al. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 2003;110:1273-1280.
118. Snow KK, Seddon JM. Do age-related macular degeneration and cardiovascular disease share common antecedents? Ophthalmic Epidemiol. 1999;6:125-143.
119. van Leeuwen R, Ikram MK, Vingerling JR, et al. Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci. 2003;44:3771-3777.
120. Vingerling JR, Dielemans I, Bots ML, et al. Age-related macular degeneration is associated with atherosclerosis: the Rotterdam Study. Am J Epidemiol. 1995;142:404-409.
121. Hirvela H, Luukinen H, Laara E, et al. Risk factors of age-related maculopathy in a population 70 years of age or older. Ophthalmology. 1996;103:871-877.
122. Vinding T. Age-related macular degeneration: an epidemiological study of 1000 elderly individuals with reference to prevalence, funduscopic findings, visual impairment, and risk factors. Acta Ophthalmol Scand. 1995;21(suppl):1-32.
123. Sperduto RD, Hiller R. Systemic hypertension and age-related macular degeneration in the Framingham Eye Study. Arch Ophthalmol. 1986;104:216-226.
124. Delaney WV, Oates RIP. Senile macular degeneration: a preliminary study. Ann Ophthalmol. 1982;14:21-24.
125. Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham Eye Study. II. Association of ophthalmic pathology with single variables previously measured in the Framingham Heart Study. Am J Epidemiol. 1977;106:33-41.
126. Vidaurri JS, Peter J, Halfon ST, et al. Association between drusen and some of the risk factors for coronary artery disease. Ophthalmologica. 1984;188:243-247.
127. Klein R, Klein BEK, Jensen SC. The relation of cardiovascular disease and its risk factors to the 5-year incidence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1997;104:1804-1812.
128. Klein R, Klein BE, Tomany SC, et al. The relation of retinal microvascular characteristics to age-related eye disease: the Beaver Dam eye study. Am J Ophthalmol. 2004;137:435-444.
129. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol. 1997;151:741-747.
130. Klein R, Klein BE, Marino EK, et al. Early age-related maculopathy in the cardiovascular health study. Ophthalmology. 2003;110:25-33.
131. van Leeuwen R, Klaver CC, Vingerling JR, et al. Cholesterol and age-related macular degeneration: is there a link? Am J Ophthalmol. 2004;137:750-752.
132. Heuberger RA, Mares-Perlman JA, Klein R, et al. Relationship of dietary fat to age-related maculopathy in the Third National Health and Nutrition Examination Survey. Arch Ophthalmol. 2001;119:1833-1838.
133. Friedman E. Dietary fat and age-related maculopathy. Arch Ophthalmol. 1996;114:235-236.
134. Klein R, Klein BEK, Moss SE. Diabetes, hyperglycemia and age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1992;99:1527-1534.
135. Snow KK, Cote J, Yang W, et al. Association between reproductive and hormonal factors and age-related maculopathy in postmenopausal women. Am J Ophthalmol. 2002;134:842-848.
136. Smith W, Mitchell P, Wang JJ. Gender oestrogen, hormone replacement and age-related macular degeneration: results from the Blue Mountains Eye Study. Aust N Z J Ophthalmol. 1997;25(suppl):13-15.
137. Klein BEK, Klein R, Jensen SC, et al. Are sex hormones associated with age-related maculopathy in women? The Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 1994;92:289-295.
138. POLA Study Group. Sex steroids and age-related macular degeneration in older French women: the POLA study. Ann Epidemiol. 2004;14:202-208.
139. Abramov Y, Borik S, Yahalom C, et al. The effect of hormone therapy on the risk for age-related maculopathy in postmenopausal women. Menopause. 2004;11:62-68.
140. Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
141. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534.
142. Johnson LV, Leitner WP, Staples MK, et al. Complement Activation and Inflammatory Process in Drusen Formation and Age Related Macular Degeneration. Exp Eye Res. 2001;73:887-896.
143. Anderson DH, Mullins RF, Hageman GS, et al. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002;134:411-431.
144. Mullins RF, Russell SR, Anderson DH, et al. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 2000;14:835-846.
145. Seddon JM, Gensler G, Milton RC, et al. Association between C-reactive protein and age-related macular degeneration. JAMA. 2004;291:704-710.
146. Klaver CC, Wolfs RC, Assink JJ, et al. Genetic risk of age-related maculopathy: population-based familial aggregation study. Arch Ophthalmol. 1998;116:1646-1651.
147. Piguet B, Wells JA, Palmvang IB, et al. Age-related Bruch's membrane change: a clinical study of the relative role of heredity and environment. Br J Ophthalmol. 1993;77:400-403.
148. Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of age-related maculopathy. Am J Ophthalmol. 1997;123:199-206.
149. Silvestri G, Johnston PB, Hughes AE. Is genetic predisposition an important risk factor in age-related macular degeneration? Eye. 1994;8:564-568.
150. Grizzard SW, Arnett D, Haag SL. Twin study of age-related macular degeneration. Ophthalmic Epidemiol. 2003;10:315-322.
151. Hammond CJ, Webster AR, Snieder H, et al. Genetic influence on early age-related maculopathy: a twin study. Ophthalmology. 2002;109:730-736.
152. Klein ML, Mauldin WM, Stoumbos VD. Heredity and age-related macular degeneration: observations in monozygotic twins. Arch Ophthalmol. 1994;112:932-937.
153. Meyers SM, Greene T, Gutman FA. A twin study of age-related macular degeneration. Am J Ophthalmol. 1995;120:757-766.
154. Heiba IM, Elston RIC, Klein BEK, et al. Sibling correlations and segregation analysis of age-related maculopathy: The Beaver Dam Eye Study. Genet Epidemiol. 1994;11:51-67.
155. Kenealy SJ, Schmidt S, Agarwal A, et al. Linkage analysis for age-related macular degeneration supports a gene on chromosome 10q26. Mol Vis. 2004;10:57-61.
156. Abecasis GR, Yashar BM, Zhao Y, et al. Age-related macular degeneration: a high-resolution genome scan for susceptibility loci in a population enriched for late-stage disease. Am J Hum Genet. 2004;74:482-494.
157. Iyengar SK, Song D, Klein BE, et al. Dissection of genomewide-scan data in extended families reveals a major locus and oligogenic susceptibility for age-related macular degeneration. Am J Hum Genet. 2004;74:20-39.
158. Schick JH, Iyengar SK, Klein BE, et al. A whole-genome screen of a quantitative trait of age-related maculopathy in sibships from the Beaver Dam Eye Study. Am J Hum Genet. 2003;72:1412-1424.
159. Weeks DE, Conley YP, Tsai HJ, et al. Age-related maculopathy: a genomewide scan with continued evidence of susceptibility loci within the 1q31, 10q26, and 17q25 regions. Am J Hum Genet. 2004;27:75.
160. Allikmets R, Seddon JM, Bernstein PS, et al. Evaluation of the Best disease gene in patients with age-related macular degeneration and other maculopathies. Hum Genet. 1999;104:449-453.
161. Allikmets R, Singh N, Sun H, et al. A photoreceptor cell-specific ATh-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet. 1997;124:331-343.
162. Baird PN, Guida E, Chu DT, et al. The epsilon2 and epsilon4 alleles of the apolipoprotein gene are associated with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2004;45:1311-1315.
163. De La Paz MA, Pericak-Vance MA, Lennon F, et al. Exclusion of TIMP3 as a candidate locus in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1997;38:1060-1065.
164. Schmidt S, Klaver C, Saunders A, et al. A pooled case-control study of the apolipoprotein E (APOE) gene in age-related maculopathy. Ophthalmic Genet. 2002;23:209-223.
165. Seddon JM, Afshari MA, Sharma S, et al. Assessment of mutations in the Best macular dystrophy (VMD2) gene in patients with adult-onset foveomacular vitelliform dystrophy, age-related maculopathy, and bull's-eye maculopathy. Ophthalmology. 2001;108:2060-2067.
166. Seddon JM, De La Paz M, Clements K, et al. No association between apolipoprotein E and advanced age-related macular degeneration. Am J Hum Genet. 1996;559:388.
167. Sun H, Nathans J. Stargardt's ABCR is localized to the disc membrane of retinal rod outer segments. Nat Genet. 1997;17:15-16.
168. Weber BHF, Vogt G, Pruett RC, et al. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nat Genet. 1994;8:352-356.
169. Zareparsi S, Reddick AC, Branham KE, et al. Association of apolipoprotein E alleles with susceptibility to age-related macular degeneration in a large cohort from a single center. Invest Ophthalmol Vis Sci. 2004;45:1306-1310.
170. Souied EH, Benlian P, Amouyel P, et al. The E4 allele of the apolipoprotein E gene as a potential protective factor for exudative age-related macular degeneration. Am J Ophthalmol. 1998;125:353-359.